Japan's Takeda To Partner With Envoy Of U.S. On Schizophrenia Drugs
This article was originally published in PharmAsia News
Executive SummaryJapan's Takeda Pharmaceutical and U.S. drug maker Envoy Therapeutics have signed an agreement to collaborate on developing schizophrenia drugs
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.